Market Cap: 70.6M


About: Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.

Employees: 103

Funds holding %
of 6,702 funds
Analysts bullish %
News positive %
of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

13% more funds holding

Funds holding: 30 [Q4 2023] → 34 (+4) [Q1 2024]

18% less capital invested

Capital invested by funds: $28.9M [Q4 2023] → $23.6M (-$5.33M) [Q1 2024]

42.75% less ownership

Funds ownership: 73.8% [Q4 2023] → 31.05% (-42.75%) [Q1 2024]

Research analyst outlook

We haven’t received any recent analyst ratings for THTX.

Financial journalist opinion

Based on 4 articles about THTX published over the past 30 days